AzTrials
AzTrials

COVID-19NCT05384912

Crowdsourcing an Open COVID-19 Imaging Repository for AI Research

An observational study of COVID-19, run by University of Central Florida at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objectives of this project are to (1) assemble a crowdsourced, de-identified radiographic repository; and (2) train and validate existing COVID-NET deep learning diagnostic models. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
COVID-19
How many people
81 participants
Where
1 siteUnited States
Study dates
18 Nov 2020to 6 Feb 2025
How long will I take part?
1 Year
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Adults over the age of 18 who have had radiographic imaging of the chest for testing of COVID-19

Who may be able to join

  • This study will include anyone in the country who has been tested for COVID-19 with a chest radiograph image.

Who cannot join

  • Patients who do not have a chest radiograph image used for COVID-19 testing

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Central Florida

    Orlando, Florida, 32827

Other trials in United States

About this study

Official title: Crowdsourcing an Open COVID-19 Chest Radiograph Imaging Repository for Artificial Intelligence Research

The objectives of this project are to (1) assemble a crowdsourced, de-identified radiographic repository; and (2) train and validate existing COVID-NET deep learning diagnostic models.

Read the detailed description

The COVID-19 pandemic is laying bare the need for accessible curated datasets that researchers can use to build clinical-grade artificial intelligence (AI) models. Researchers in China recently used deep learning models of clinical-grade AI trained on radiographic imaging at an exponential scale to detect COVID-19 cases and optimize allocation of limited resources. (Jin S, Wang B, Xu H, et al. Ai-assisted ct imaging analysis for covid-19 screening: Building and deploying a medical ai system in four weeks. medRxiv. 2020:2020.2003.2019.20039354. doi: 10.1101/2020.03.19.20039354). This research platform is currently not possible in the United States because there are no large accessible radiographic image sets of COVID-19 patients to leverage. Therefore, the purpose of this project is to launch an interactive and HIPAA-compliant web portal-CovidImaging.com-where patients can securely share their radiographic imaging data. This portal will serve as an imaging repository for the purpose of training, testing, and validating an AI model aimed at earlier and more accurate disease detection in this global fight against COVID-19.

On January 30, 2020 the World Health Organization designated the COVID-19 outbreak that originated in Wuhan, China as a global health emergency. Since then, the virus has rapidly spread across the world as a pandemic, unfavorably affecting health care systems at the expense of primary healthcare requirements.1Symptomatic cases of COVID-19 present with clinical symptoms similar to viral pneumonia such as fever, shortness of breath, chills, fatigue, cough, and dyspnea that can progress to acute respiratory distress syndrome, requiring critical care and ventilation. 2 Bronchoalveolar lavage analysis and electron microscopy identified the causative agent to be a novel, positive-sense RNA virus in the Coronaviridae family, with spiked peplomers attached to its envelope.3 This family of viruses has also been associated with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which cause similar pneumonia-related mortality.

Preliminary reviews have been conducted to investigate the overlap of reported imaging features in SARS, MERS, and COVID-19 as it relates to onset of symptoms, progression of disease, and follow up. Early evidence suggests significant overlap in imaging features such as subpleural and peripheral areas of ground-glass opacity and consolidation, with initial chest imaging indicating abnormality in at least 85% of COVID-19 patients. 4 In the absence of vaccines and specific therapeutic drugs for the prevention and treatment of COVID-19, detection of the disease plays a vital role in containment strategies that isolate infected people from the healthy population. Even though RT-PCR sensitivity for COVID-19 can be as low as 60-70%, it is currently the large-scale method of testing with its high specificity.7 The low sensitivity of RT-PCR, along with limitations of sample collection, time delay, transportation, and lab equipment, means that not enough COVID-19 positive people are being identified in time to prevent progressive infection of this highly contagious virus. Given the respiratory involvement in COVID-19 infections, chest radiography has played an important role in screening, diagnosing, and developing treatment plans for patients with COVID-19-related pneumonia. Therefore, combining imaging with clinical and laboratory findings could facilitate the early diagnosis of COVID-19.5 Early detection would speed up treatment and allow for early patient isolation. This is essential for the implementation of public health surveillance, containment, and response for a highly communicable disease in which transmission can occur prior to onset of symptoms. Improving the precision of radiographic interpretation with AI models may improve detection rate and patient prognosis and thus help to reduce COVID-19 spread.

As recently reported, chest CT demonstrates common radiographic features in almost all COVID-19 patients, including ground-glass 4 opacities, multifocal patchy consolidation, and/or interstitial changes with a peripheral distribution. 8,9 Studies have also been conducted to compare the efficacy and diagnostic value of chest CT to RT-PCR tests in COVID-19 cases. A case report of 1014 patients in China concluded that chest CT has a high sensitivity for diagnosis of COVID-19, with 60% to 93% of cases showing initial positive CT diagnosis prior to the initial positive RT-PCR results. 10 Another study with 51 patients having chest CT and RT-PCR assay within 3 days showed that the sensitivity of CT for COVID-19 infection was 98%, compared to 71% RT-PCR sensitivity.11 These studies further indicate the diagnostic value of chest radiographs alongside clinical and laboratory findings. This project will develop a large radiographic image repository which will be used to train and validate an AI deep learning model. This project necessarily involves not only designing and refining a deep learning model, but also curating a repository of donated chest radiographs that will be used to train the novel model. Using a secure and HIPAA-complaint online platform, as has been designed for this project, will allow this project to employ a big data approach to improve the accuracy of the model. Since patients from healthcare facilities around the country will have equal opportunity to participate in the project, this portal will also provide an opportunity to expand the demographic pool in a way that previous studies could not.

Conditions
COVID-19
Keywords
COVID, AI, Crowdsourcing, X-rays, Radiology
Medical subject headings
COVID-19

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assemble a crowdsourced, de-identified radiographic repository

    Measured: Same Day

Secondary outcomes (1)
  1. Train and validate existing COVID-NET deep learning diagnostic models

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 May 2022
  2. Study start18 Nov 2020
  3. Primary completion6 Feb 2025
  4. Study completion6 Feb 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Other
Enrolment
81 participants (actual)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT05384912
Sponsor's protocol ID
STUDY00001804
Status last verified
Aug 2025
First submitted
18 May 2022
Last updated
28 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of COVID-19, run by University of Central Florida at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assemble a crowdsourced, de-identified radiographic repository (time frame: Same Day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in